Premium
AMILORIDE IN THE TREATMENT OF PRIMARY HYPERALDOSTERONISM AND ESSENTIAL HYPERTENSION
Author(s) -
KREMER D.,
BODDY K.,
BROWN J. J.,
DAVIES D. L.,
FRASER R.,
LEVER A. F.,
MORTON J. J.,
ROBERTSON J. I. S.
Publication year - 1977
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1977.tb01307.x
Subject(s) - amiloride , hyperaldosteronism , medicine , endocrinology , blood pressure , aldosterone , plasma renin activity , sodium , essential hypertension , potassium , angiotensin ii , hypokalemia , sodium bicarbonate , renin–angiotensin system , chemistry , organic chemistry
SUMMARY Amiloride (40 mg/day) was given to nineteen patients with primary hyperaldosteronism. There were significant falls in systolic and diastolic blood pressure, in total exchangeable sodium, and in serum sodium and bicarbonate; while total exchangeable potassium, total body potassium, serum potassium, chloride and urea, and plasma renin, angiotensin II and aldosterone all increased significantly. Amiloride was effective in reducing blood pressure in patients with and without adrenocortical adenoma. No carry‐over effect was seen on withdrawing amiloride. Similar changes were associated with amiloride treatment in five patients with essential hypertension; hyperkalaemia was not observed. Only negligible side‐effects were encountered in the entire series of twenty‐four patients.